Venus Concept 2025 Q3 Earnings Revenue Misses as Net Loss Widens 142.4%

Venus Concept (VERO) reported Q3 2025 earnings, with revenue declining 8.2% year-over-year to $13.78 million, missing the $14.48 million consensus estimate. The company also widened its net loss to $22.55 million, a 142.4% increase from the prior year. Venus Concept did not provide 2025 full-year guidance, citing ongoing strategic and financial challenges.

Revenue

Venus Concept’s Q3 revenue fell 8.2% to $13.78 million, driven by a 12% drop in U.S. revenue and a 3% decline internationally. Within the segment breakdown, Products-Systems remained the largest contributor at $7.86 million, while Venus Prime/Subscription-Systems generated $2.94 million. Products-Other added $2.33 million, and Services revenue stood at $647,000. The decline was attributed to softness in the hair restoration business and delayed closure of its pending sale.

Earnings/Net Income

The company’s net loss surged to $22.55 million in Q3 2025, a 142.4% increase from $9.30 million in the prior year. GAAP EPS worsened to -$12.14, narrowing by $0.96 per share year-over-year. Despite a slight improvement in EPS, the net loss remains a critical concern, reflecting persistent operational and financial headwinds.

Price Action

The stock price of Venus Concept edged up 2.35% on the latest trading day but plummeted 9.84% over the past week and 26.89% month-to-date.

The strategy of buying VERO shares on quarterly earnings release dates and holding for 30 days has underperformed significantly, with a 3-year cumulative return of -68.77% and an average quarterly return of -22.61%. This poor performance highlights challenges in capitalizing on the company’s revenue trends.

Post-Earnings Price Action Review

Venus Concept’s stock has struggled post-earnings, with a 2.35% intraday gain failing to offset a 9.84% weekly decline and a 26.89% monthly drop. The 3-year cumulative return of -68.77% from a strategy of buying shares on earnings dates and holding for 30 days underscores the stock’s inability to capitalize on revenue growth. Investors remain cautious, reflecting skepticism about the company’s ability to turn around its financial performance.

CEO Commentary

CEO Rajiv De Silva emphasized the company’s focus on strategic initiatives, including the limited launch of Venus Nova in December 2025, targeting the GLP-1 medication market. He noted the platform’s potential to address skin laxity and body contouring needs, aligning with long-term growth goals. Despite ongoing losses, the leadership remains cautiously optimistic about sequential revenue growth in Q4 and the eventual closure of the Venus Hair Business sale.

Additional News

Within three weeks of the earnings report, Venus Concept announced FDA 510(k) clearance for its Venus Nova platform, a key product launch expected to drive future growth. The company also completed a $11.5 million debt-to-equity exchange, reducing total debt by 24% to $30.1 million. Additionally, legal proceedings were initiated to resolve delays in the $20 million sale of its Venus Hair Business to Meta Healthcare Group, a transaction critical to refocusing on its core medical aesthetics operations.